Jean-Baptiste Bossard1, Camille Ponté2, Julie Dupouy1,3, Maryse Lapeyre-Mestre1,2, Emilie Jouanjus4,5. 1. Equipe de Pharmacoepidemiologie, UMR1027-Université Paul Sabatier Toulouse III, 37 allées Jules Guesde, 31000, Toulouse, France. 2. CEIP-Addictovigilance, Service de Pharmacologie Médicale et Clinique, CHU Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France. 3. Département Universitaire de Médecine Générale, Université Paul Sabatier Toulouse III, Faculté de Médecine, 133, route de Narbonne, Toulouse, 31062, France. 4. Equipe de Pharmacoepidemiologie, UMR1027-Université Paul Sabatier Toulouse III, 37 allées Jules Guesde, 31000, Toulouse, France. emilie.jouanjus@univ-tlse3.fr. 5. CEIP-Addictovigilance, Service de Pharmacologie Médicale et Clinique, CHU Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France. emilie.jouanjus@univ-tlse3.fr.
Abstract
BACKGROUND AND OBJECTIVE: Pregabalin abuse and dependence has been increasingly described; however, it is not described in France. Our study aimed to investigate the abuse and dependence potential of pregabalin by a disproportionality analysis, in the French Pharmacovigilance Database (FPVD), in comparison with amitriptyline and clonazepam. METHODS: We performed a case/noncase study in the FPVD. Between January, 1 2010 and December, 31 2015, we identified cases of abuse and or dependence (excluding isolated withdrawal syndromes) using MedDRA (Medical Dictionary for Regular Activities) terms. Exposure to pregabalin was defined as the mention of pregabalin in the report. Clonazepam was used as positive control and amitriptyline as negative control. RESULTS: Among the 184,310 reports in the database, 521 were abuse or dependence cases. Exposure to pregabalin was found in eight (1.5 %) of them. We did not find any significant association between exposure to pregabalin and drug abuse or dependence: reporting odds ratio (ROR) = 1.1 95 % confidence interval (CI) (0.6-2.3). ROR for clonazepam was 5.7 95 % CI (3.5-9.2). No case of an amitriptyline-related abuse or dependence was recorded in the FPVD. CONCLUSIONS: The first cases of pregabalin-related abuse or dependence reported in France occurred later than in other European countries, since none had been described before 2010. This analysis in the FPVD did not find a higher proportion of abuse/dependence with pregabalin in comparison with other drugs. Considering evidence of pregabalin abuse worldwide, this analysis underlines the limitations of spontaneous reporting system in the field of addictovigilance.
BACKGROUND AND OBJECTIVE: Pregabalin abuse and dependence has been increasingly described; however, it is not described in France. Our study aimed to investigate the abuse and dependence potential of pregabalin by a disproportionality analysis, in the French Pharmacovigilance Database (FPVD), in comparison with amitriptyline and clonazepam. METHODS: We performed a case/noncase study in the FPVD. Between January, 1 2010 and December, 31 2015, we identified cases of abuse and or dependence (excluding isolated withdrawal syndromes) using MedDRA (Medical Dictionary for Regular Activities) terms. Exposure to pregabalin was defined as the mention of pregabalin in the report. Clonazepam was used as positive control and amitriptyline as negative control. RESULTS: Among the 184,310 reports in the database, 521 were abuse or dependence cases. Exposure to pregabalin was found in eight (1.5 %) of them. We did not find any significant association between exposure to pregabalin and drug abuse or dependence: reporting odds ratio (ROR) = 1.1 95 % confidence interval (CI) (0.6-2.3). ROR for clonazepam was 5.7 95 % CI (3.5-9.2). No case of an amitriptyline-related abuse or dependence was recorded in the FPVD. CONCLUSIONS: The first cases of pregabalin-related abuse or dependence reported in France occurred later than in other European countries, since none had been described before 2010. This analysis in the FPVD did not find a higher proportion of abuse/dependence with pregabalin in comparison with other drugs. Considering evidence of pregabalin abuse worldwide, this analysis underlines the limitations of spontaneous reporting system in the field of addictovigilance.
Authors: Martin Grosshans; Jochen Mutschler; Derik Hermann; Oliver Klein; Harald Dressing; Falk Kiefer; Karl Mann Journal: Am J Psychiatry Date: 2010-07 Impact factor: 18.112
Authors: Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham Journal: Clin Drug Investig Date: 2021-02-12 Impact factor: 2.859
Authors: Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749